Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

  • Horng-Yuan Lou
  • Chun-Chao Chang
  • Ming-Thau Sheu
  • Ying-Chen Chen
  • Hsiu-O Ho
Pharmacogenetics

Abstract

Objective

In this pilot study, we attempted to determine the optimal dosage regimens of esomeprazole for treatment of GERD with minimal influence of the CYP2C19 polymorphism through a study of the pharmacokinetics and pharmacodynamics of esomeprazole given at 3 different dosage regimens with the same total daily dose.

Methods

Each of the 3genotypes of CYP2C19, homozygous extensive metabolizers (homEMs), heterozygous EMS (hetEMs), and poor metabolizers (PMs) were recruited in this clinical trial. Subjects were given a placebo followed by the administration of esomeprazole, at a dose of 40 mg once daily (40QD), 20 mg twice daily (20TD), or 10 mg 4 times daily (10Q4D) for 7 days. Twenty-four-hour and nocturnal intragastric pH and plasma esomeprazole concentrations were all determined on day 7.

Results

The pharmacokinetic parameters and dynamic characteristics differed among the 3 CYP2C19 genotype groups. With esomeprazole 40QD, gastric acid suppression was insufficient to achieve a therapeutic effect, while 20TD and 10Q4D were found to be effective in controlling both daytime and nocturnal gastric acidity for all 3 genotype groups.

Conclusions

It was confirmed that intragastric pH values and plasma esomeprazole concentrations potentially depended on the CYP2C19 genotype status for treatment with esomeprazole. Dosage regimens of divided doses of 20TD or 10Q4D esomeprazole yielded improved antisecretory effects with a minimal influence of CYP2C19 polymorphisms.

Keywords

GERD Esomeprazole CYP2C19 Polymorphism Intragastric pH 

References

  1. 1.
    Orr WC (2005) Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 17:113–120PubMedCrossRefGoogle Scholar
  2. 2.
    Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, Carlsson E (2003) Esomeprazole - enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 17:481–488PubMedCrossRefGoogle Scholar
  3. 3.
    Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl. 1):59–67PubMedCrossRefGoogle Scholar
  4. 4.
    Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A et al (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191–6PubMedCrossRefGoogle Scholar
  5. 5.
    Peghini PL, Katz PO, Castell DO (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115:1335–1339PubMedCrossRefGoogle Scholar
  6. 6.
    Miner P Jr, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616–2620PubMedCrossRefGoogle Scholar
  7. 7.
    Thomson A, Claar-Nilsson C, Hasselgren G, Niazi M, Rohss K, Nyman L (2000) Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut 47(Suppl. 3):A63 (Abstract)Google Scholar
  8. 8.
    Lind T, Rydberg L, Kyleback A et al (2000) Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861–867PubMedCrossRefGoogle Scholar
  9. 9.
    Röhss K, Hasselgren G, Hedenström H (2002) Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 47:954–958PubMedCrossRefGoogle Scholar
  10. 10.
    Wilder-Smith C, Röhss K, Lundin C, Rydholm H (2000) Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 118:A22–23CrossRefGoogle Scholar
  11. 11.
    Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K (2002) Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GORD. J Gastroenterol Hepatol 17(Suppl.):A612 (Abstract)Google Scholar
  12. 12.
    Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB (2004) Intragastric acid suppression and pharmacokinelics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 20:399–406PubMedCrossRefGoogle Scholar
  13. 13.
    Galmiche JP, Bruley S, Varannes DES, Ducrotte P, Sacher-Huvelin S, Vavasseur F et al (2004) Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 19:655–662PubMedCrossRefGoogle Scholar
  14. 14.
    Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763–767PubMedCrossRefGoogle Scholar
  15. 15.
    Katz PO, Anderson C, Khoury R, Castell DO (1998) Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231–1234PubMedCrossRefGoogle Scholar
  16. 16.
    Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, Kinoshita Y (2000) Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049–1056PubMedCrossRefGoogle Scholar
  17. 17.
    Stedman CAM, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963–978PubMedCrossRefGoogle Scholar
  18. 18.
    Hassan-Alin M, Andersson T, Niazi M, Röhss K (2005) A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 60:779–784PubMedCrossRefGoogle Scholar
  19. 19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S (2006) Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Therapeutics 79:144–1452CrossRefGoogle Scholar
  20. 20.
    Robinson M (2004) The pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications. Aliment Pharmacol Ther 20:1–10PubMedCrossRefGoogle Scholar
  21. 21.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai MO, Ishizaki T (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290–301PubMedCrossRefGoogle Scholar
  22. 22.
    Sheu B-S, Kao A-W, Cheng H-C, Hunag S-F, Chen T-W, Lu C-C, Wu J-J (2005) Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 21:283–288PubMedCrossRefGoogle Scholar
  23. 23.
    Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G (2005) Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 78:627–634PubMedCrossRefGoogle Scholar
  24. 24.
    De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S- mephenytoin metabolism in humans. J Biol Chem 269:15419–15422PubMedGoogle Scholar
  25. 25.
    Adachi K, Komazawa Y, Fujishiro H, Mihara T, Ono M, Yuki M et al (2003) Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subject: effects of different regimens. J Gastroenterol 38:830–835PubMedCrossRefGoogle Scholar
  26. 26.
    Wagner JG (1979) Fundamentals of Clinical Pharmacokinetics, 2nd edn. Drug Intelligence Publications, Inc., Hamilton, IL, pp 36–7Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Horng-Yuan Lou
    • 1
  • Chun-Chao Chang
    • 1
  • Ming-Thau Sheu
    • 2
  • Ying-Chen Chen
    • 2
  • Hsiu-O Ho
    • 2
    • 3
  1. 1.Division of Gastroenterology, Department of Internal MedicineTaipei Medical University and HospitalTaipeiTaiwan
  2. 2.College of PharmacyTaipei Medical UniversityTaipeiTaiwan
  3. 3.TaipeiTaiwan

Personalised recommendations